Induction of aberrant vascular growth, but not of normal angiogenesis, by cell-based expression of different doses of human and mouse VEGF is species-dependent

Human Gene Therapy Methods

Volumn 24, Issue 1, 2013, Pages 28-37

  Mujagic, Edin ^a   Gianni Barrera, Roberto ^a   Trani, Marianna ^a   Patel, Abdulsamie ^a   Gürke, Lorenz ^a   Heberer, Michael ^a   Wolff, Thomas ^a   Banfi, Andrea ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN 165;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; MYOBLAST; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; CELLS, CULTURED; CLONING, MOLECULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; ISCHEMIA; KINETICS; MICE; MICE, INBRED C57BL; MICE, SCID; MUSCLE, SKELETAL; MYOBLASTS; NEOVASCULARIZATION, PATHOLOGIC; RETROVIRIDAE; SEQUENCE ANALYSIS, DNA; SIGNAL TRANSDUCTION; SPECIES SPECIFICITY; TRANSDUCTION, GENETIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

MURINAE; MUS;

EID: 84878306806     PISSN: 19466536     EISSN: 19466544     Source Type: Journal    
DOI: 10.1089/hgtb.2012.197     Document Type: Article

References (31)

1. Banfi, A., Springer, M.L., and Blau, H.M. (2002). Myoblastmediated gene transfer for therapeutic angiogenesis. Methods Enzymol. 346, 145-57.
2. Banfi, A., Von Degenfeld, G., and Blau, H.M. (2005). Critical role of microenvironmental factors in angiogenesis. Curr. Atheroscler. Rep. 7, 227-34.
3. Banfi, A., Von Degenfeld, G., Gianni-Barrera, R., et al. (2012). Therapeutic angiogenesis due to balanced single-vector delivery of VEGF and PDGF-BB. FASEB J 26, 2486-97.
4. Carmeliet, P. (2000). VEGF gene therapy: stimulating angiogenesis or angioma-genesis? Nat. Med. 6, 1102-3.
5. Carmeliet, P. (2003). Angiogenesis in health and disease. Nat. Med. 9, 653-60.
6. Gianni-Barrera, R., Trani, M., Fontanellaz, C., et al. (2013). VEGF over-expression in skeletal muscle induces angiogenesis by intussusception rather than sprouting. Angiogenesis 16, 123-36.
7. Gupta, R., Tongers, J., and Losordo, D.W. (2009). Human studies of angiogenic gene therapy. Circ. Res. 105, 724-36.
8. Isner, J.M., Pieczek, A., Schainfeld, R., et al. (1996). Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet 348, 370-4.
9. Karvinen, H., and Yla-Herttuala, S. (2010). New aspects in vascular gene therapy. Curr. Opin. Pharmacol. 10, 208-11.
10. Karvinen, H., Pasanen, E., Rissanen, T.T., et al. (2011). Long-term VEGF-A expression promotes aberrant angiogenesis and fibrosis in skeletal muscle. Gene Ther. 18, 1166-72.
11. Korpisalo, P., Hytonen, J.P., Laitinen, J.T., et al. (2011). Capillary enlargement, not sprouting angiogenesis, determines beneficial therapeutic effects and side effects of angiogenic gene therapy. Eur. Heart J. 32, 1664-72.
12. Lee, R.J., Springer, M.L., Blanco-Bose, W.E., et al. (2000). VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation 102, 898-901.
13. Misteli, H., Wolff, T., Fuglistaler, P., et al. (2010). Highthroughput flow cytometry purification of transduced progenitors expressing defined levels of vascular endothelial growth factor induces controlled angiogenesis in vivo. Stem Cells 28, 611-9.
14. Norgren, L., Hiatt, W.R., Dormandy, J.A., et al. (2007). Intersociety consensus for the management of peripheral arterial disease (TASC II). J. Vasc. Surg. 45 Suppl S, S5-67.
15. Ozawa, C.R., Banfi, A., Glazer, N.L., et al. (2004). Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. J. Clin. Invest. 113, 516-27.
16. Park, J.E., Keller, G.A., and Ferrara, N. (1993). The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol. Biol. Cell. 4, 1317-26.
17. Pettersson, A., Nagy, J.A., Brown, L.F., et al. (2000). Heterogeneity of the angiogenic response induced in different normal adult tissues by vascular permeability factor/vascular endothelial growth factor. Lab. Invest. 80, 99-115.
18. Rando, T.A., and Blau, H.M. (1994). Primary mouse myoblast purification, characterization, and transplantation for cellmediated gene therapy. J. Cell Biol. 125, 1275-87.
19. Ruhrberg, C., Gerhardt, H., Golding, M., et al. (2002). Spatially restricted patterning cues provided by heparin-binding VEGFA control blood vessel branching morphogenesis. Genes Dev. 16, 2684-98.
20. Schwarz, E.R., Speakman, M.T., Patterson, M., et al. (2000). Evaluation of the effects of intramyocardial injection of DNA expressing vascular endothelial growth factor (VEGF) in a myocardial infarction model in the rat - angiogenesis and angioma formation. J. Am. Coll. Cardiol. 35, 1323-30.
21. Schweighofer, B., Testori, J., Sturtzel, C., et al. (2009). The VEGFinduced transcriptional response comprises gene clusters at the crossroad of angiogenesis and inflammation. Thromb. Haemost. 102, 544-54.
22. Springer, M.L., and Blau, H.M. (1997). High-efficiency retroviral infection of primary myoblasts. Somat. Cell Mol. Genet. 23, 203-9.
23. Springer, M.L., Chen, A.S., Kraft, P.E., et al. (1998). VEGF gene delivery to muscle: potential role for vasculogenesis in adults. Mol. Cell. 2, 549-58.
24. Springer, M.L., Ozawa, C.R., Banfi, A., et al. (2003). Localized arteriole formation directly adjacent to the site of VEGFinduced angiogenesis in muscle. Mol. Ther. 7, 441-9.
25. Tagawa, M., Nakauchi, H., Herzenberg, L.A., and Nolan, G.P. (1986). Formal proof that different-size Lyt-2 polypeptides arise from differential splicing and post-transcriptional regulation. Proc. Natl. Acad. Sci. USA 83, 3422-6.
26. Von Degenfeld, G., Banfi, A., Springer, M.L., et al. (2006). Microenvironmental VEGF distribution is critical for stable and functional vessel growth in ischemia. FASEB J 20, 2657-9.
27. Witzenbichler, B., Maisonpierre, P.C., Jones, P., et al. (1998). Chemotactic properties of angiopoietin-1 and - 2, ligands for the endothelial-specific receptor tyrosine kinase Tie2. J. Biol. Chem. 273, 18514-21.
28. Wolff, T., Mujagic, E., Gianni-Barrera, R., et al. (2012). FACSpurified myoblasts producing controlled VEGF levels induce safe and stable angiogenesis in chronic hind limb ischemia. J. Cell. Mol. Med. 16, 107-17.
29. Yla-Herttuala, S. (2006). An update on angiogenic gene therapy: vascular endothelial growth factor and other directions. Curr. Opin. Mol. Ther. 8, 295-300.
30. Yla-Herttuala, S., Markkanen, J.E., and Rissanen, T.T. (2004). Gene therapy for ischemic cardiovascular diseases: some lessons learned from the first clinical trials. Trends Cardiovasc. Med. 14, 295-300.
31. Zacchigna, S., Tasciotti, E., Kusmic, C., et al. (2007). In vivo imaging shows abnormal function of vascular endothelial growth factor-induced vasculature. Hum. Gene Ther. 18, 515-24.